Recently, we have shown that Ehmt2 inactivation antagonizes oncogenic Kras-mediated pancreatic cancer initiation and promotion by altering growth and immune gene expression networks (Urrutia et al., 2021). The gene discussed is KRAS; the disease is pancreatic neoplasm.